TYP logo

Tryptamine Therapeutics ASX:TYP Stock Report

Last Price

AU$0.045

Market Cap

AU$60.0m

7D

-8.2%

1Y

n/a

Updated

21 Nov, 2024

Data

Company Financials

Tryptamine Therapeutics Limited

ASX:TYP Stock Report

Market Cap: AU$60.0m

TYP Stock Overview

A clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. More details

TYP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Tryptamine Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tryptamine Therapeutics
Historical stock prices
Current Share PriceAU$0.045
52 Week HighAU$0.057
52 Week LowAU$0.017
Beta0
11 Month Change136.84%
3 Month Change125.00%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO73.08%

Recent News & Updates

Recent updates

Shareholder Returns

TYPAU PharmaceuticalsAU Market
7D-8.2%-11.8%1.5%
1Yn/a39.8%17.2%

Return vs Industry: Insufficient data to determine how TYP performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how TYP performed against the Australian Market.

Price Volatility

Is TYP's price volatile compared to industry and market?
TYP volatility
TYP Average Weekly Movement17.5%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.6%
10% most volatile stocks in AU Market17.3%
10% least volatile stocks in AU Market3.4%

Stable Share Price: TYP's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine TYP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2019n/aJason Carrollwww.tryptherapeutics.com

Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome.

Tryptamine Therapeutics Limited Fundamentals Summary

How do Tryptamine Therapeutics's earnings and revenue compare to its market cap?
TYP fundamental statistics
Market capAU$59.99m
Earnings (TTM)-AU$7.37m
Revenue (TTM)AU$1.33m

43.3x

P/S Ratio

-7.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TYP income statement (TTM)
RevenueAU$1.33m
Cost of RevenueAU$2.35m
Gross Profit-AU$1.02m
Other ExpensesAU$6.35m
Earnings-AU$7.37m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0058
Gross Margin-76.85%
Net Profit Margin-555.37%
Debt/Equity Ratio3.5%

How did TYP perform over the long term?

See historical performance and comparison